We are excited to announce that Imad al Ghouleh, PhD, has received the 2017 Gilead Research Scholars Award in Pulmonary Arterial Hypertension. The mission of this program is to support innovative scientific research that will advance knowledge and understanding in the field of PAH. (Source)
The Vascular Medicine Institute has been well-represented at the Gilead Research Scholars Program. Other VMI researchers who have received this award include:
VMI investigators Elena Goncharova, PhD, and Stephen Chan, MD, PhD study how pulmonary hypertension develops in order to design better therapeutic interventions to prevent, regress, or cure this devastating cardiopulmonary disease. During the past year, both investigators have made remarkable discoveries in the molecular pathways that cause remodeling of pulmonary vascular tissue and limit blood flow between the heart and lungs. These discoveries will help identify drug targets that are likely to stop or significantly slow the disease progression.
Dr. Goncharova and her laboratory discovered a new mechanism that drives pathogenic proliferation and impairs apoptosis of vascular smooth muscle cells in small pulmonary arteries. They found that HIPPO, a key growth suppressor cassette that prevents organ overgrowth, is dysfunctional in small pulmonary arteries of patients with pulmonary arterial hypertension. This results in activation of transcriptional co-activators YAP and TAZ, unleash other pro-proliferative pro-survival signaling pathways and increases cell proliferation and survival. The researchers identified ILK1 as a key molecule that “locks” HIPPO in inactive state and showed that pharmacological inhibition of ILK1 restores HIPPO function and stops the cyclical process of molecular activations that causes dangerous cell proliferation and apoptosis resistance in pulmonary hypertension patients’ arteries. Selective ILK inhibitors can now be further explored as a promising strategy for therapeutic intervention to reverse pulmonary hypertension.
Dr. Chan and his laboratory discovered a novel link between pulmonary vessel wall stiffening and the way that these blood vessels create energy and biomass. Dr. Chan’s group found that this link is primarily controlled by the activation of YAP and TAZ which in turn control an enzyme called glutaminase. Activation of glutaminase sets in motion a metabolic process that ends in dangerous cell proliferation in the arteries of pulmonary hypertension patients. The Chan lab identified the YAP inhibitor verteporfin and the glutaminase inhibitor CB-839 as therapeutic drug candidates when used, either singly or together, can impede the molecular pathways driving this deadly disease.
New Procedure Aims to Improve Quality of Life for CTEPH Patients - UPMC & Pitt Health Sciences News Blog
Experts from the UPMC Comprehensive Pulmonary Hypertension Program are now using a new procedure aimed at improving the quality of life for chronic thromboembolic pulmonary hypertension (CTEPH) patients who aren't responding to medication or are ineligible for surgery.
Once again, in celebration of Pulmonary Hypertension Month, the UPMC PH Program, in collaboration with PH researchers at the University of Pittsburgh’s Vascular Medicine Institute, hosted Research Day for Patients.
On November 22, 2016, PH patients and their guests were updated on the newest PH research innovations and discoveries, and clinical trials. Scientists in the Vascular Medicine Institute were honored to welcome PH patients into their laboratories to get a behind-the-scenes tour of the facilities where our cutting-edge research happens.
In November 2016, Dr. Stephen Chan was interviewed by MD Magazine about better understanding PH, diagnosing PH, and improving treatment of PH. You can view the videos below or at this link.